GlassScriptPhysician profile
Sonia L Ali
NPI 1730451089
$14,545.38
in general payments reported to CMS, 2019-2025
47 companies · $1,192 in 2025
The $1,192 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,994 · 2020: $3,098 · 2021: $271 · 2022: $452 · 2023: $557 · 2024: $980 · 2025: $1,192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,730.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,730.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $7,682.56 | 2019-2022 | |
| Seagen INC. | $1,951.29 | 2020-2023 | Tukysa |
| Glaxosmithkline, LLC. | $1,134.53 | 2020-2025 | Jemperli, Zejula |
| Pfizer INC. | $394.36 | 2019-2025 | |
| Abbvie INC. | $314.64 | 2020-2025 | Venclexta |
| Merck Sharp & Dohme LLC | $193.10 | 2019-2025 | Keytruda, Lynparza |
| Daiichi Sankyo INC. | $184.73 | 2021-2025 | Vanflyta, Enhertu |
| Lilly USA, LLC | $183.58 | 2019-2020 | |
| Genentech USA, INC. | $173.78 | 2019-2025 | Venclexta, Phesgo |
| Astellas Pharma US INC | $160.24 | 2024-2025 | Xospata, Cresemba |
| Takeda Pharmaceuticals U.S.A., INC. | $159.09 | 2019-2025 | Alunbrig, Ninlaro |
| Astrazeneca Pharmaceuticals LP | $135.45 | 2019-2025 | Imfinzi, Tagrisso |
| Karyopharm Therapeutics INC. | $110.44 | 2020-2025 | Xpovio |
| Beigene USA, INC. | $108.20 | 2023-2024 | Brukinsa |
| Novartis Pharmaceuticals Corporation | $105.64 | 2024-2025 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Springworks Therapeutics, INC. | $101.43 | 2024-2025 | Ogsiveo |
| Incyte Corporation | $101.43 | 2019-2025 | Jakafi, Monjuvi |
| Celgene Corporation | $98.22 | 2019-2025 | Reblozyl, Opdivo |
| Kite Pharma, INC. | $95.20 | 2020-2025 | Yescarta |
| Coherus Oncology, INC. | $88.05 | 2023-2024 | |
| Pharmaessentia USA Corporation | $84.87 | 2022-2024 | Besremi |
| Eisai INC. | $82.71 | 2020-2024 | |
| Stemline Therapeutics INC. | $82.04 | 2023-2025 | Orserdu, Elzonris |
| Tersera Therapeutics LLC | $71.10 | 2023-2025 | Xermelo, Zoladex |
| Ipsen Biopharmaceuticals, INC | $61.28 | 2023 | Onivyde, Somatuline Depot, Tazverik |
| Sobi, INC | $55.28 | 2024 | |
| Exelixis INC. | $51.73 | 2019-2025 | Cabometyx |
| Pharmacyclics LLC, An Abbvie Company | $50.64 | 2022 | |
| Gilead Sciences, INC. | $46.95 | 2021-2025 | Trodelvy |
| Bayer Healthcare Pharmaceuticals INC. | $45.31 | 2024-2025 | |
| Fennec Pharmaceuticals, INC. | $44.33 | 2024-2025 | Fyarro, Pedmark |
| Genzyme Corporation | $44.10 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $40.55 | 2019-2024 | Opdivo |
| Taiho Oncology, INC. | $28.82 | 2024 | |
| Puma Biotechnology, INC. | $28.53 | 2025 | |
| Deciphera Pharmaceuticals INC. | $27.39 | 2024 | Qinlock |
| West Therapeutics Development, LLC | $26.13 | 2019 | |
| Janssen Biotech, INC. | $25.47 | 2025 | Erleada |
| Csl Behring | $23.12 | 2025 | Afstyla, Idelvion |
| Genmab U.S., INC. | $21.65 | 2023 | Epkinly |
| Blueprint Medicines Corporation | $21.63 | 2021 | |
| Array Biopharma INC | $20.47 | 2025 | Mektovi, Lorbrena, Braftovi |
| Jazz Pharmaceuticals INC. | $20.00 | 2020 | |
| Tempus Ai, INC | $19.69 | 2024 | |
| Sumitomo Pharma America, INC. | $18.74 | 2023 | Orgovyx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.75 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonia Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.